From: Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
Age group (years)
Utility value[24]
<16
0.91
16-24
25-34
35-44
0.88
45-54
0.85
55-64
0.79
65-74
0.78
≥75
0.73